Can you take Chloramphenicol / hydrocortisone / polymyxin b ophthalmic with Orforglipron?

The chloramphenicol ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible. The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection. It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy. Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued. A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity. It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug. Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression. Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy. Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.

The hydrocortisone ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Cataract.

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.

Orforglipron has a moderate potential interaction with Dehydration.

There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.

Orforglipron has a moderate potential interaction with Diabetes Mellitus.

Orforglipron lowers blood glucose and can cause hypoglycemia. In diabetic patients, blood glucose should be monitored before starting and during treatment with orforglipron.

Orforglipron has a moderate potential interaction with Diabetic Retinopathy.

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Orforglipron has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy during treatment with orforglipron.

Orforglipron has a moderate potential interaction with Diarrhea.

There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.

The hydrocortisone ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Eye Conditions.

The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation. In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents. Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy. If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.

Orforglipron has a moderate potential interaction with Gastroparesis.

Use of orforglipron has been associated with gastrointestinal adverse reactions (sometimes severe). Orforglipron is not recommended in patients with severe gastroparesis.

The hydrocortisone ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Glaucoma/Intraocular Hypertension.

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.

Orforglipron has a moderate potential interaction with Liver Disease.

Orforglipron is not recommended for patients with severe liver dysfunction (Child-Pugh C). No dose adjustment is needed for patients with mild or moderate liver dysfunction (Child-Pugh A or B).

Orforglipron has a major potential interaction with Multiple Endocrine Neoplasia Type II.

Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of orforglipron and should be informed of symptoms of thyroid tumors.

Orforglipron has a major potential interaction with Thyroid Tumor.

Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of orforglipron and should be informed of symptoms of thyroid tumors.

Orforglipron has a moderate potential interaction with Vomiting.

There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.